Side Effects & Safety Typical first-cycle side effects: Weeks 1-2: mild water retention, vivid dreams, light head/warmth after injection Weeks 3-4: occasional joint stiffness, improved sleep quality, slight appetite increase overnight Weeks 5-8: adaptation phase most side effects fade, body composition changes visible Clinical discontinuation signals (trial-reported): Clinical participants in tesamorelin studies were discontinued upon experiencing: Persistent headaches with visual changes (intracranial pressure marker in trial monitoring protocols) Sustained fasting glucose elevation of ~15 mg/dL above baseline Unusual peripheral swelling persisting beyond weeks 1-2 Carpal tunnel symptoms unresponsive to dose titration in community-reported protocols Tesamorelin has been studied at 2mg/day for 6+ months without notable safety signals at therapeutic doses

This method of more direct delivery helps to ensure that patients will receive the maximum benefit from the nutrients, as they are quickly absorbed and subsequently utilized by the cells
Philadelphia, PA: Saunders, Elsevier Science
Overall pain, overall mobility, and overall sleep
There were only a few single drug interventions in the clinical trials summarized in this article as most of the trials were drugs combined with chemotherapy